<DOC>
	<DOCNO>NCT00249145</DOCNO>
	<brief_summary>The purpose study compare safety efficacy risperidone ( antipsychotic medication ) placebo treatment behavioral disturbance associate dementia .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Treatment Behavioral Disturbances Patients With Dementia</brief_title>
	<detailed_description>Dementia term use collection symptom cause number disease injury affect brain . Individuals dementia loss function cognition ( think , perception , learning , verbal communication , memory , judgment ) , may lead behavioral personality change ( example , agitation , delusion , hallucination ) . Some cause dementia reversible ; however , irreversible dementia cause certain condition , Alzheimer 's disease . Dementia common elderly individual , normal part age . This randomized , double-blind , parallel-group , placebo-controlled study compare effectiveness safety risperidone placebo patient behavioral disturbance associate dementia . Haloperidol include reference therapy confirm efficacy analyse valid . The study compose two period : 1-week run-in period patient discontinue antipsychotic drug take placebo twice daily 12-week double-blind treatment period . At end run-in period , patient randomly assign one three risperidone dos , placebo , haloperidol ( oral solution ) . The start dose risperidone haloperidol 0.25 milligram ( mg ) twice daily , increase gradually maximum dose 2 mg/day . If patient sufficient response , dose gradually increase maximum 4 mg/day . The patient receive dos remainder double-blind period . The primary measure effectiveness reduction &gt; = 30 % baseline end double-blind treatment total Behavior Pathology Alzheimer 's Disease Rating Scale ( BEHAVE-AD ) score . The BEHAVE-AD rating scale use evaluate behavior symptom patient Alzheimer 's disease . Additional efficacy measure include Clinical Global Impressions ( CGI ) , rating system use evaluate overall severity clinical change patient various disease affect brain ; Cohen-Mansfield Agitation Inventory ( CMAI ) , questionnaire evaluate agitation ; Functional Assessment Staging ( FAST ) , diagnostic tool determine stage dementia ; Mini-Mental State Examination ( MMSE ) , clinical measure use evaluate cognition . Safety evaluation include incidence adverse event ; result clinical laboratory test ( hematology , biochemistry , urinalysis ) ; measurement vital sign ; physical neurological examination electrocardiogram ( ECG ) finding ; evaluation presence severity sedation ; compute tomography ( CT ) scan brain ; Extrapyramidal Symptoms Rating Scale ( ESRS ) , scale use measure effect antipsychotic medication motor function patient . The study hypothesis risperidone effective placebo , measure change baseline total BEHAVE-AD score , treat behavioral disturbance demented patient . Risperidone oral solution 1 mg/mL ; haloperidol oral solution , 1 mg/mL ; placebo oral solution . Starting dose 0.25 mg twice daily increase 2 mg/day . If 2 mg/day show insufficient response , maximum 4 mg/day risperidone haloperidol permit . Total treatment duration 12 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients dementia Alzheimer 's type , mixed dementia , vascular dementia , ( classify Diagnostic Statistical Manual Mental Diseases , 4th edition [ DSMIV ] ) behavioral disturbance score &gt; =4 FAST score &lt; =23 MMSE BEHAVEAD total score &gt; =8 , BEHAVEAD global rating &gt; =1 must institutionalize . Patients medical neurological condition cognition ( think , perception , learning , verbal communication , memory , judgment ) diminish ( example , drug overdosage , severe liver , heart , lung , kidney malfunction , Parkinson 's disease ) psychiatric disorder , include major depression , schizophrenia , substance abuse dependence abnormal electrocardiogram ( ECG ) finding abnormal clinical laboratory test finding .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>vascular dementia</keyword>
	<keyword>mixed dementia , risperidone</keyword>
	<keyword>nursing home</keyword>
</DOC>